High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease

Journal of Internal Medicine

Volumn 274, Issue 3, 2013, Pages 252-262

  Baragetti, A ^a,b   Norata, G D ^a,b,c   Sarcina, C ^a   Rastelli, F ^a   Grigore, L ^a   Garlaschelli, K ^a   Uboldi, P ^b   Baragetti, I ^a   Pozzi, C ^a   Catapano, A L ^b,d  

^a Bassini Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

ABCA 1; Cholesterol efflux; Chronic kidney disease; Dialysis; HDL; SR BI

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ABCA-1; CHOLESTEROL EFFLUX; CHRONIC KIDNEY DISEASE; DIALYSIS; HDL; SR-BI;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; ROC CURVE; SCAVENGER RECEPTORS, CLASS B;

EID: 84881551580     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12081     Document Type: Article

References (43)

1. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-21.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
3. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-9.
4. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-80.
5. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008; 21: 635-44.
6. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-60.
7. Mak RH, Ikizler TA, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Erratum to: wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011; 2: 119.
8. Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr 2009; 90: 407-14.
9. Castledine C, van Schalkwyk D, Feest T, Steenkamp R, Dawnay A. UK Renal Registry 13th Annual Report (December 2010): chapter 10: calcium, phosphate, parathyroid hormone, bicarbonate and total cholesterol concentrations amongst patients receiving haemodialysis or peritoneal dialysis in England, Wales and Northern Ireland in 2009: national and centre-specific analyses. Nephron Clin Pract 2011; 119(Suppl 2): c179-214.
10. Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010; 33: 100-10.
11. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-6.
12. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009; 22: 644-51.
13. Holzer M, Birner-Gruenberger R, Stojakovic T et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011; 22: 1631-41.
14. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012; 222: 299-306.
15. Boscutti G, Calabresi L, Pizzolitto S et al. LCAT deficiency: a nephrological diagnosis. G Ital Nefrol 2011; 28: 369-82.
16. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol 2004; 287: F1038-43.
17. Homma S, Murayama N, Yoshida I et al. Marked atherosclerosis in a patient with familiar lecithin: cholesterol acyltransferase deficiency associated with end-stage renal disease and diabetes mellitus. Am J Nephrol 2001; 21: 415-19.
18. Predazzi IM, Norata GD, Vecchione L et al. Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. PLoS ONE 2012; 7: e31086.
19. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag 2007; 3: 783-95.
20. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279-84.
21. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
22. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
23. Ammirati E, Cianflone D, Banfi M et al. Circulating CD4 + CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1832-41.
24. Norata GD, Baragetti I, Raselli S et al. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 2010; 20: 56-63.
25. Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N. Comment on: American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl. 1):S11-61. Diabetes Care 2011; 34: e53; author reply e4.
26. Ammirati E, Cianflone D, Vecchio V et al. Effector memory T cells are associated with atherosclerosis in humans and animal models. J Am Heart Assoc 2012; 1: 27-41.
27. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 2006; 37: 1558-61.
28. Lorenz MW, Bickel H, Bots ML et al. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a meta-analysis project. Am Heart J 2010; 159(730-6): e2.
29. Norata GD, Grigore L, Raselli S et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007; 193: 321-7.
30. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
31. Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time course of flow-mediated dilatation in humans. Hypertension 2008; 51: 203-10.
32. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-35.
33. Zhou H, Tan KC, Shiu SW, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 927-33.
34. Pirillo A, Norata GD, Catapano AL. High-density lipoprotein subfractions - what the clinicians need to know. Cardiology 2013; 124: 116-25.
35. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46.
36. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
37. Morton J, Zoungas S, Li Q et al. Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy: results of the ADVANCE study. Diabetes Care 2012; 35: 2201-6.
38. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-91.
39. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995; 26: 670-5.
40. Yamamoto S, Yancey PG, Ikizler TA et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012; 60: 2372-9.
41. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006; 69: 440-9.
42. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003; 63: S207-10.
43. Marz W, Genser B, Drechsler C et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6: 1316-25.